Funding round brings in $25 million for Versartis

01/16/2013 | American City Business Journals

Versartis secured $25 million from new and existing investors in a Series C financing round. Proceeds will support clinical trials of VRS-317, an investigational once-monthly form of recombinant human growth hormone designed for children with growth hormone deficiency. "With this substantial funding, we are able to continue our comprehensive development program for VRS-317, including obtaining proof-of-concept efficacy results and preparing for the launch of a Phase III trial in 2014," Versartis CEO Jeffrey Cleland said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC